Cancer Management in Saudi Arabia: Recommendations by the Saudi Oncology HeAlth Economics ExpeRt GrouP (SHARP)

Alkhudair, Nora; Alshamrani, Majed; Samarkandi, Hadeel; Almodaheem, Hajer; Alabdulkarim, Hana; Alsaqa'aby, M.; Alnajjar, Fouad; Al-Hashem, Hashem; Bakkar, Mohammed; Bazarbashi, Shouki; AlNahedh, Mohammed; Alfraih, Feras; Alawagi, Mohammad; Al‐Jedai, Ahmed

doi:10.1016/j.jsps.2020.12.005

Cited by 6 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Q-OHEP, comprising members of the HMC, NCCCR, MOPH, QU, QCS, and Sidra Medicine, convened on 30 November 2021 for a 3-hour meeting to discuss several aspects of cancer management, therapeutics, and health economics in Qatar, following the objectives listed above. Discussions focused on four domains based on previously published literature on similar experiences [15] as well as adaptations from guidelines for the formulation of consensus-based recommendations [16]: (1) regulatory, (2) procurement, (3) treatment, and (4) patients. Discussions, guided by a moderator, were focused on a list of suggested open-ended questions (Table 1).…”

Section: Methodsmentioning

confidence: 99%

“…2. Implement models that enable decision-making based on value according to current health economic principles, such as health technology assessment and multiple-criteria decision analysis, to enhance or complement the traditional cost-effectiveness studies commonly used to appraise cancer medicines in regional [15] and international settings [18].…”

Section: Value-based Optionsmentioning

confidence: 99%

“…There is lack of published data on similar work from the region except Saudi Arabia [15], where the healthcare system and population demographics, although have many similarities, are not exactly the same. We believe we had the best experts in Qatar (relevant to the study topic) in our panel, however expert consensus papers by nature are presenting the views of participating experts.…”

Section: Study Limitationsmentioning

confidence: 99%

See 2 more Smart Citations

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

Hamad

Elazzazy

Bujassoum

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

Background In line with global trends, cancer incidence and mortality may have decreased for specific types of cancer in Qatar. However, the cancer-related burden on patients, healthcare systems, and the economy is expected to expand; thus, cancer remains a significant public healthcare issue in Qatar. Qatar’s free access to cancer care represents a considerable economic burden. Ensuring the best utilization of financial resources in the healthcare sector is important to provide unified and fair access to cancer care for all patients. Experts from the Qatar Oncology Health Economics Expert Panel (Q-OHEP) aimed to establish a consistent and robust base for evaluating oncology/hematology medications; involve patients’ insights to accelerate access to cutting-edge medications; increase the value of cancer care; and reach a consensus for using cost-effective strategies and efficient methodologies in cancer treatment. Methods The Q-OHEP convened on 30 November 2021 for a 3-hour meeting to discuss cancer management, therapeutics, and health economics in Qatar, focusing on four domains: (1) regulatory, (2) procurement, (3) treatment, and (4) patients. Discussions, guided by a moderator, focused on a list of suggested open-ended questions. Results Some of the salient recommendations included the development of a formal, fast-track, preliminary approval pathway for drugs needed by patients with severe disease or in critical condition; and encouraging and promoting the conduct of local clinical trials and real-world observational studies using existing registry data. The Q-OHEP also recommended implementing a forecast system using treatment center data based on the supply/demand of formulary oncology drugs to detect treatment patterns, estimate needs, expedite procurement, and prevent shortages/delays. Furthermore, the panel discussed the needs to define value concerning cancer treatment in Qatar, implement value-based models for reimbursement decision-making such as health technology assessment and multiple-criteria decision analysis, and promote patient education and involvement/feedback in developing and implementing cancer management guidelines. Conclusion Herein, we summarize the first Q-OHEP consensus recommendations, which aim to provide a solid basis for evaluating, registering, and approving new cancer medications to accelerate patient access to novel cancer treatments in Qatar; promote/facilitate the adoption and collection of patient-reported outcomes; and implement value-based cancer care in Qatar.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Value-based Optionsmentioning

confidence: 99%

Section: Study Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

Hamad

Elazzazy

Bujassoum

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…The Q-OHEP, comprising members of the HMC, NCCCR, MOPH, QU, QCS, and Sidra Medicine, convened on 30 November 2021 for a 3-hour meeting to discuss several aspects of cancer management, therapeutics, and health economics in Qatar, following the objectives listed above. Discussions focused on four domains based on previously published literature on similar experiences [13] as well as adaptations from guidelines for the formulation of consensus-based recommendations [14]: (1) regulatory, (2) procurement, (3) treatment, and (4) patients. Discussions, guided by a moderator, were focused on a list of suggested open-ended questions (Table 1).…”

Section: Methodsmentioning

confidence: 99%

“…2. Implement models that enable decision-making based on value according to current health economic principles, such as health technology assessment or multiple-criteria decision analysis, to enhance or complement the traditional cost-effectiveness studies commonly used to appraise cancer medicines in regional [13] and international settings [16]. 3.…”

Section: Value-based Optionsmentioning

confidence: 99%

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

Hamad

Elazzazy

Bujassoum

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: In line with global trends, cancer incidence and mortality may have decreased for specific types of cancer in Qatar. However, the cancer-related burden on patients, healthcare systems, and the economy is expected to expand; thus, cancer remains a significant public healthcare issue in Qatar. Qatar’s free access to cancer care represents a considerable economic burden. Ensuring the best utilization of financial resources in the healthcare sector is important to provide unified and fair access to cancer care for all patients. Experts from the Qatar Oncology Health Economics Expert Panel (Q-OHEP) aimed to establish a consistent and robust base for evaluating oncology/hematology medications; involve patients’ insights to accelerate access to cutting-edge medications; increase the value of cancer care; and reach a consensus for using cost-effective strategies and efficient methodologies in cancer treatment. Methods: The Q-OHEP convened on 30 November 2021 for a 3-hour meeting to discuss cancer management, therapeutics, and health economics in Qatar, focusing on four domains: (1) regulatory, (2) procurement, (3) treatment, and (4) patients. Discussions, guided by a moderator, focused on a list of suggested open-ended questions. Results: Some of the salient recommendations included the development of a formal, fast-track, preliminary approval pathway for drugs needed by patients with severe disease or in critical condition; and encouraging and promoting the conduct of local clinical trials and real-world observational studies using existing registry data. The Q-OHEP also recommended implementing a forecast system using treatment center data based on the supply/demand of formulary oncology drugs to detect treatment patterns, estimate needs, expedite procurement, and prevent shortages/delays. Furthermore, the panel discussed the needs to define value concerning cancer treatment in Qatar, implement models for decision-making based on said value according to health technology assessment or multiple-criteria decision analysis, and promote patient education and involvement/feedback in developing and implementing cancer management guidelines. Conclusions: Herein, we summarize the first Q-OHEP consensus recommendations, which aim to provide a solid basis for evaluating, registering, and approving new cancer medications to accelerate patient access to novel cancer treatments in Qatar; promote/facilitate the adoption and collection of patient-reported outcomes; and implement value-based cancer care in Qatar.

show abstract

Ambulatory care hematology/oncology pharmacy services: A comprehensive review by the Saudi Oncology Pharmacy Assembly

Alsuhebany,

Alkhudair,

Alzahrani

et al. 2024

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Saudi Vision 2030 has driven significant changes in ambulatory care pharmacy services in the Kingdom of Saudi Arabia (KSA), transitioning pharmaceutical care from inpatient to outpatient settings. With a growing need to address non‐communicable diseases, particularly cancer, ambulatory care oncology pharmacy services are of paramount importance. This study aims to evaluate the potential benefits and challenges of establishing such services in the KSA and offers recommendations for clinical pharmacists. A comprehensive literature search was conducted using PubMed, MEDLINE, EMBASE, and Google Scholar, encompassing research from inception to September 2023. The search focused on English language studies related to ambulatory care oncology/hematology pharmacy services. Among the 1351 studies found, those assessing the impact of clinical pharmacists on patient outcomes in outpatient oncology clinics were included. The review of the literature highlights the substantial impact of clinical pharmacists in outpatient hematology/oncology settings. A selection of several studies revealed their role in improving patient care, reducing health care costs, and enhancing treatment outcomes. Notable findings include a high acceptance rate of pharmacist interventions with significant cost savings, increased pharmacist involvement in patient encounters, and reduced emergency department visits and inpatient admissions due to pharmacist interventions. These results showed the valuable contributions of clinical pharmacists in the international outpatient oncology setting. Establishing ambulatory care hematology/oncology pharmacy services in Saudi Arabia is critical, considering the rising cancer burden. The value of specialized oncology clinical pharmacists in the outpatient setting is emphasized by various studies conducted in the United States. This review proposes a framework for patient‐centered oncology practices, serving as a valuable resource for the strategic development of ambulatory care oncology pharmacy services in Saudi Arabia. These efforts align with Saudi Vision 2030's broader goals of enhancing health care quality and patient care.

show abstract

Cancer Management in Saudi Arabia: Recommendations by the Saudi Oncology HeAlth Economics ExpeRt GrouP (SHARP)

Cited by 6 publications

References 17 publications

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

Ambulatory care hematology/oncology pharmacy services: A comprehensive review by the Saudi Oncology Pharmacy Assembly

Contact Info

Product

Resources

About